Generic Name: brolucizumab
Brand Name: TBC
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Indications: Macular degeneration, age-related
Manufacturer Requested Reimbursement Criteria1:
For the treatment of neovascular (wet) age-related macular degeneration.
Submission Type: New
Project Status: Pending
Call For Patient Input: August 28, 2019
Patient Input Closed: October 18, 2019
Anticipated Date: September 26, 2019
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.